GLP-1 Drugs for Menopause-Related Obesity and Symptoms: What We Know | Research

The takeaway

GLP-1 RA effects in menopausal/postmenopausal women are not well characterized, with potential differences from other populations due to hormonal changes, body composition shifts, and unique symptom profiles.

Understudied population
Menopausal women are among the largest GLP-1 drug user groups but are significantly underrepresented in clinical trials

What the researchers found

GLP-1 RA effects in menopausal/postmenopausal women may differ from other populations due to hormonal changes affecting body composition and metabolism, with limited direct evidence available.

Why it matters

Menopausal women are a large GLP-1 drug user group but are understudied. Understanding sex- and hormone-specific effects is crucial for personalized prescribing.

How the study worked

Review of evidence on GLP-1 RA effects specifically in menopausal and postmenopausal women.

What this study cannot tell us

Limited direct evidence. Most GLP-1 trials don't stratify by menopausal status. Extrapolation from general populations may be inaccurate.

How to read the evidence

Review identifying evidence gaps. Limited direct evidence for this specific population.

When this study was published

Published in 2025.

The bigger picture

This highlights a major gender and age gap in GLP-1 drug research that needs to be addressed as these drugs become standard care for millions of women.

Questions still open

Do menopausal women lose proportionally more lean mass on GLP-1 drugs?
Could GLP-1 drugs affect bone density in postmenopausal women?
Should HRT be combined with GLP-1 therapy for optimal menopausal weight management?

Common questions

Do GLP-1 drugs work differently after menopause?

We don't have enough data to know for certain. Menopausal hormonal changes affect how the body processes fat and muscle, which could alter GLP-1 drug effects. More research specifically in menopausal women is needed.

Should menopausal women be cautious with GLP-1 drugs?

The drugs likely work for weight loss, but menopausal women should pay extra attention to muscle mass and bone density monitoring, as hormonal changes already increase risks in these areas.

Read the original research

Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) for Obesity and Symptoms in Menopause: A Review.

Cureus, 18(1), e101693

View on PubMed ↗Publisher’s paper ↗

Citation

Graczyk, Nicole A; Bisschops, Julia. (2026). Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) for Obesity and Symptoms in Menopause: A Review.. Cureus, 18(1), e101693. https://doi.org/10.7759/cureus.101693